Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reconsolidation Blockade for PTSD (PARIS-MEM)
NCT02789982Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of propranolol in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: PTSD Checklist - Specific at 12 months, Medical resources use at 12 months and 1 more. Started May 2016; status: completed.
02
Drugs
propranolol
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT02789982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02789982.